Identification

Name
Tetracaine
Accession Number
DB09085
Type
Small Molecule
Groups
Approved, Vet Approved
Description

Tetracaine is an ester local anaesthetic currently available in combination with lidocaine as a cream and patch.

Structure
Thumb
Synonyms
  • 2-(dimethylamino)ethyl 4-(butylamino)benzoate
  • 2-(Dimethylamino)ethyl p-(butylamino)benzoate
  • Amethocaine
  • Amethocaine HCl
  • Diäthylaminoäthanol ester der p-butylaminobenzösäure
  • Dicaine
  • Medihaler-Tetracaine
  • Metraspray
  • p-(butylamino)benzoic acid β-(dimethylamino)ethyl ester
  • p-Butylaminobenzoyl-2-dimethylaminoethanol
  • Tetracaína
  • Tétracaïne
  • Tetracaine HCl
Product Ingredients
IngredientUNIICASInChI Key
Tetracaine hydrochloride5NF5D4OPCI136-47-0PPWHTZKZQNXVAE-UHFFFAOYSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ametop Gel 4%Gel40 mgTopicalSmith & Nephew, Inc.1998-03-16Not applicableCanada
PontocainePowder, for solution20 mgIntraspinalHospira, Inc.2001-07-15Not applicableCanada
Pontocaine 5 mg/mlSolution0.5 %OphthalmicHospira, Inc.2001-06-01Not applicableCanada
Pontocaine Dps 0.5%Solution / drops.5 %OphthalmicSanofi1937-12-312001-08-10Canada
Pontocaine Pws Inj 20mg/ampPowder, for solution20 mgIntraspinalSanofi1951-12-312001-08-10Canada
Supracaine Aerosol 11.6mg/gmAerosol, metered11.6 mgOral; TopicalHoechst Roussel Canada Inc.1993-12-312000-07-28Canada
Tetracaine HydrochlorideSolution5 mg/mLOphthalmicAlcon, Inc.1969-03-28Not applicableUs
Tetracaine HydrochlorideSolution5 mg/mLOphthalmicA S Medication Solutions1969-03-282017-06-20Us
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Blt 3Ointment2 g/100gTopicalCentura Pharmaceuticals, Inc2016-10-30Not applicableUs
Burn CreamCream10 mg/mLTopicalBio Medical & Pharmaceutical Manufacturing Corporation2016-08-19Not applicableUs
Burn Solution CreamCream10 mg/mLTopicalBurn Solution Foundations2016-08-23Not applicableUs
Comfortox TetracaineCream20 mg/1000mgTopicalSambria Pharmaceuticals2016-09-14Not applicableUs
Eclipse Topical Analgesic LLCream20 mg/1000mgTopicalSambria Pharmaceuticals2016-02-01Not applicableUs
Minims Tetracaine Hydrochloride 0.5%Solution / drops0.5 %OphthalmicValeant Canada Lp Valeant Canada S.E.C.1995-12-31Not applicableCanada
Minims Tetracaine Hydrochloride 1%Solution / drops1 %OphthalmicValeant Canada Lp Valeant Canada S.E.C.1995-12-31Not applicableCanada
NeuroMed LACream20 mg/mLTopicalSambria Pharmaceuticals2015-12-222016-10-13Us
NeuroMed Topical Analgesic LACream20 mg/1000mgTopicalSambria Pharmaceuticals2016-02-01Not applicableUs
Numfast Tetracaine GreenCream20 mg/gTopicalUnit Dose, Ltd.2016-01-20Not applicableUs
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AltacaineSolution5 mg/mLOphthalmicAltaire Pharmaceuticals Inc.2002-02-01Not applicableUs
NiphanoidInjection, powder, for solution10 mg/mLSubarachnoidHospira, Inc.1997-06-092016-10-26Us
TetracaineInjection10 mg/mLSubarachnoidAkorn2010-06-01Not applicableUs
Tetracaine HydrochlorideSolution5 mg/mLOphthalmicCentral Texas Community Health Centers1990-09-30Not applicableUs
Tetracaine HydrochlorideSolution5 mg/mLOphthalmicLake Erie Medical Dba Quality Care Produts Llc1990-09-30Not applicableUs
Tetracaine HydrochlorideSolution5 mg/mLOphthalmicA S Medication Solutions1990-09-302017-06-20Us
Tetracaine HydrochlorideSolution5 mg/mLOphthalmicPreferreed Pharmaceuticals Inc.2013-05-16Not applicableUs
Tetracaine HydrochlorideSolution5 mg/mLOphthalmicRemedy Repack2015-08-252017-02-17Us
Tetracaine HydrochlorideSolution5 mg/mLOphthalmicBauch & Lomb Incorporated1990-09-30Not applicableUs
Tetracaine HydrochlorideSolution5 mg/mLOphthalmicNu Care Pharmaceuticals,inc.1990-09-30Not applicableUs
International/Other Brands
Pontocaine / Pontocaine HCl
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Cetacaine AnestheticTetracaine hydrochloride (.004 g/.2g) + Benzocaine (.028 g/.2g) + Butamben (.004 g/.2g)Aerosol, sprayTopicalCetylite Industries, Inc.1958-01-01Not applicableUs
Cetacaine AnestheticTetracaine hydrochloride (.004 g/.2g) + Benzocaine (.028 g/.2g) + Butamben (.004 g/.2g)SolutionTopicalCetylite Industries, Inc.1960-01-01Not applicableUs
Cetacaine LiquidTetracaine hydrochloride (2 %) + Benzocaine (14 %) + Butamben (2 %)LiquidTopicalCetylite Industries, Inc.1996-09-19Not applicableCanada
Cetacaine SprayTetracaine hydrochloride (2 %) + Benzocaine (14 %) + Butamben (2 %)AerosolTopicalCetylite Industries, Inc.1994-12-31Not applicableCanada
Cetacaine Topical AnestheticTetracaine hydrochloride (.004 g/.2g) + Benzocaine (.028 g/.2g) + Butamben (.004 g/.2g)GelTopicalCetylite Industries, Inc.1960-01-01Not applicableUs
Cetacaine Topical AnestheticTetracaine hydrochloride (.004 g/.2g) + Benzocaine (.028 g/.2g) + Butamben (.004 g/.2g)GelTopicalCetylite Industries, Inc.1960-01-01Not applicableUs
CutiecaineTetracaine (20 mg/g) + Benzocaine (180 mg/g)CreamTopicalInnovatech Inc2010-08-31Not applicableUs
Denti-Care Denti-Freeze Topical Anesthetic BubblegumTetracaine hydrochloride (.02 g/g) + Benzocaine (.18 g/g)GelDentalAr Medicom Inc.2000-02-01Not applicableUs
Denti-Care Denti-Freeze Topical Anesthetic CherryTetracaine hydrochloride (.02 g/g) + Benzocaine (.18 g/g)GelDentalAr Medicom Inc.2000-04-01Not applicableUs
Denti-care Denti-freeze Topical Anesthetic GelTetracaine hydrochloride (2 %) + Benzocaine (18 %)GelTopicalAr Medicom Inc.2009-04-16Not applicableCanada
Categories
UNII
0619F35CGV
CAS number
94-24-6
Weight
Average: 264.369
Monoisotopic: 264.183778021
Chemical Formula
C15H24N2O2
InChI Key
GKCBAIGFKIBETG-UHFFFAOYSA-N
InChI
InChI=1S/C15H24N2O2/c1-4-5-10-16-14-8-6-13(7-9-14)15(18)19-12-11-17(2)3/h6-9,16H,4-5,10-12H2,1-3H3
IUPAC Name
2-(dimethylamino)ethyl 4-(butylamino)benzoate
SMILES
CCCCNC1=CC=C(C=C1)C(=O)OCCN(C)C

Pharmacology

Indication

The combination lidocaine and tetracaine patch is indicated for local dermal analgesia for superficial dermatological procedures and superficial venous access. The combination lidocaine and tetracaine cream is intended to provide topical local analgesia for superficial dermatological procedures.

Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action

Tetracaine is an ester-type anesthetic and produces local anesthesia by blocking the sodium ion channels involved in initiation and conduction of neuronal impulses.

TargetActionsOrganism
ARyanodine receptor 1
modulator
Human
ARyanodine receptor 2
modulator
Human
AVoltage gated sodium channel
antagonist
human
Absorption

Systemic absorption of anaesthetic from the combination cream is directly related to the duration and surface area of application. Although peak plasma concentrations for lidocaine were measured, plasma levels for tetracaine could not be determined due to low levels (<0.9 ng/mL)

Volume of distribution

Tetracaine is rapidly hydrolyzed in the plasma; therefore, volume of distribution could not be determined.

Protein binding

Tetracaine is rapidly hydrolyzed in the plasma; therefore, protein binding could not be determined.

Metabolism

Tetracaine is rapidly hydrolyzed by plasma esterases to the following primary metabolites: para-aminobenzoic acid and diethylaminoethanol. The activity of both metabolites is unspecified.

Route of elimination
Not Available
Half life

Tetracaine is hydrolyzed rapidly in the plasma; therefore, half-life has not been determined.

Clearance

Tetracaine is hydrolyzed rapidly in the plasma; therefore, clearance has not been determined.

Toxicity

The most common adverse effects with the combination cream are localized reactions such as: erythema (47%), skin discoloration (16%), and edema (14%). Systemic adverse events were less common, occurring at a rate of <1% and included vomiting, headache, dizziness, and fever. Similar to other amide and ester anesthetics, CNS excitation and/or depression may occur. It is not well known at which plasma concentration systemic toxicity occurs with tetracaine; however, the threshold is thought to be much lower than that of lidocaine which is 1000 ng/mL.

Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Tetracaine.Experimental
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Tetracaine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Tetracaine.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Adipiplon is combined with Tetracaine.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Tetracaine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Tetracaine is combined with Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Tetracaine is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Tetracaine.Approved, Illicit
AllopregnanoloneThe risk or severity of adverse effects can be increased when Tetracaine is combined with Allopregnanolone.Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Tetracaine.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Tetracaine.Approved, Illicit, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Tetracaine.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Amitriptyline.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Tetracaine.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Tetracaine.Experimental
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Tetracaine.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Tetracaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Tetracaine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Tetracaine is combined with Azaperone.Vet Approved
AzelastineTetracaine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Tetracaine is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Tetracaine.Illicit
BenperidolThe risk or severity of adverse effects can be increased when Tetracaine is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Tetracaine.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Tetracaine.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Tetracaine is combined with Brexpiprazole.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Tetracaine.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Tetracaine.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Tetracaine is combined with Bromisoval.Experimental
BromperidolThe risk or severity of adverse effects can be increased when Tetracaine is combined with Bromperidol.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Tetracaine.Approved, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Tetracaine.Approved, Investigational
BuprenorphineTetracaine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Tetracaine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Tetracaine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Tetracaine is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Tetracaine is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Tetracaine.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Tetracaine.Approved, Illicit, Vet Approved
CanertinibThe risk or severity of adverse effects can be increased when Canertinib is combined with Tetracaine.Investigational
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Tetracaine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Tetracaine.Illicit, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Tetracaine is combined with Carisoprodol.Approved
CetirizineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Tetracaine.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Tetracaine.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Tetracaine.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Tetracaine.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Chlorphenamine.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Tetracaine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Tetracaine.Approved, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Tetracaine is combined with Chlorzoxazone.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Tetracaine.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Tetracaine is combined with Citalopram.Approved
ClemastineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Tetracaine is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Tetracaine is combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Tetracaine.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Tetracaine is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Clonidine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Tetracaine is combined with Clopenthixol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Tetracaine.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Clothiapine.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Tetracaine.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Tetracaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Tetracaine.Approved, Illicit
CyclizineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Tetracaine.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Cyproheptadine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Tetracaine is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Tetracaine.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Dapoxetine.Investigational
DeramciclaneThe risk or severity of adverse effects can be increased when Deramciclane is combined with Tetracaine.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Tetracaine.Approved
DesipramineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Tetracaine.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Tetracaine.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Tetracaine.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Tetracaine.Approved
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Tetracaine.Approved, Illicit, Vet Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Tetracaine is combined with Diethyl ether.Experimental
DifenoxinThe risk or severity of adverse effects can be increased when Tetracaine is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Tetracaine.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Tetracaine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Tetracaine.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Tetracaine is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Tetracaine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Tetracaine.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Dixyrazine.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Tetracaine is combined with Doramectin.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Tetracaine is combined with Doxepin.Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Tetracaine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Tetracaine.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Tetracaine.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Tetracaine.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Tetracaine.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Tetracaine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Tetracaine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Tetracaine is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Tetracaine is combined with Efavirenz.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Tetracaine is combined with Eltanolone.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Tetracaine.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Tetracaine is combined with Entacapone.Approved, Investigational
EscitalopramThe risk or severity of adverse effects can be increased when Tetracaine is combined with Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Tetracaine.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Tetracaine.Approved
EthanolTetracaine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Tetracaine.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Tetracaine is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Tetracaine is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Tetracaine.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Tetracaine is combined with Ethyl chloride.Experimental
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Tetracaine.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Tetracaine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Tetracaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Tetracaine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Tetracaine is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Tetracaine.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Tetracaine is combined with Etoperidone.Approved
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Tetracaine.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Tetracaine is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Tetracaine.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Tetracaine.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Tetracaine is combined with Flibanserin.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Tetracaine is combined with Fluanisone.Experimental
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Tetracaine.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Tetracaine.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Tetracaine.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Tetracaine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Tetracaine.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Tetracaine.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Tetracaine is combined with Fluticasone propionate.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Tetracaine.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when Tetracaine is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Tetracaine.Approved, Illicit
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Tetracaine.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Tetracaine is combined with Gabapentin Enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Tetracaine.Approved, Illicit
GepironeThe risk or severity of adverse effects can be increased when Tetracaine is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Tetracaine.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Tetracaine.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Tetracaine.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Tetracaine.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Tetracaine.Approved, Illicit
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Tetracaine.Approved
HyaluronidaseThe risk or severity of adverse effects can be increased when Hyaluronidase is combined with Tetracaine.Approved, Investigational
HydrocodoneTetracaine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Tetracaine.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Tetracaine.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Tetracaine is combined with Iloperidone.Approved
ImipramineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Indalpine.Investigational, Withdrawn
IndiplonThe risk or severity of adverse effects can be increased when Tetracaine is combined with Indiplon.Investigational
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Tetracaine.Approved, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Tetracaine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Tetracaine.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Tetracaine.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Lamotrigine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Tetracaine is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Tetracaine.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Tetracaine is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Tetracaine.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Tetracaine is combined with Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Tetracaine.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Tetracaine.Approved, Vet Approved
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Tetracaine.Approved
LofentanilThe risk or severity of adverse effects can be increased when Tetracaine is combined with Lofentanil.Illicit
LoprazolamThe risk or severity of adverse effects can be increased when Tetracaine is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Tetracaine.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Tetracaine is combined with Lormetazepam.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Tetracaine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Tetracaine.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Tetracaine.Approved, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Maprotiline.Approved
MebicarThe risk or severity of adverse effects can be increased when Tetracaine is combined with Mebicar.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Tetracaine is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Tetracaine.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Tetracaine is combined with Melperone.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Tetracaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Tetracaine.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Tetracaine is combined with Meptazinol.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Tetracaine.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Tetracaine is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Tetracaine.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Tetracaine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Tetracaine.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Tetracaine.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Tetracaine is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Tetracaine.Approved
MethotrimeprazineTetracaine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Tetracaine.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Tetracaine is combined with Methsuximide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Tetracaine.Experimental
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Tetracaine.Approved
MetyrosineTetracaine may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Tetracaine.Approved, Illicit
MilnacipranThe risk or severity of adverse effects can be increased when Tetracaine is combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Tetracaine.Approved, Investigational
MirtazapineTetracaine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Tetracaine.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Tetracaine.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Tetracaine.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Tetracaine.Approved
NefazodoneThe risk or severity of adverse effects can be increased when Tetracaine is combined with Nefazodone.Approved, Withdrawn
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Tetracaine.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Tetracaine.Approved, Vet Approved
NorfluraneThe risk or severity of adverse effects can be increased when Tetracaine is combined with Norflurane.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Tetracaine is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Nortriptyline.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Tetracaine.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Tetracaine.Approved
OpiumThe risk or severity of adverse effects can be increased when Tetracaine is combined with Opium.Approved, Illicit
OrphenadrineTetracaine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Tetracaine.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Tetracaine.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Oxethazaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Tetracaine.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Tetracaine.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Tetracaine.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Tetracaine.Approved, Investigational, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Tetracaine.Approved
ParaldehydeTetracaine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Paroxetine.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Tetracaine is combined with Penfluridol.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Tetracaine.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Tetracaine.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Tetracaine.Approved
PerazineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Perazine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Tetracaine.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Tetracaine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Tetracaine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Phenazocine.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Tetracaine is combined with Phenibut.Experimental
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Tetracaine.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Phenoperidine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Tetracaine is combined with Phenoxyethanol.Approved
PhenytoinThe risk or severity of adverse effects can be increased when Tetracaine is combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Tetracaine.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Tetracaine is combined with Pipamperone.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Pipotiazine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Tetracaine is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Tetracaine is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Tetracaine is combined with Pomalidomide.Approved
PramipexoleTetracaine may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Tetracaine.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Tetracaine.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Tetracaine.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Tetracaine is combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Tetracaine.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Tetracaine.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Tetracaine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Promethazine.Approved
PropanididThe risk or severity of adverse effects can be increased when Tetracaine is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Tetracaine.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Tetracaine.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Propoxycaine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Protriptyline.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Tetracaine is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Tetracaine.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Tetracaine.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Tetracaine.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Tetracaine is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Tetracaine is combined with Ramelteon.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Tetracaine.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Tetracaine.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Tetracaine.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Tetracaine.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Tetracaine is combined with Ritanserin.Investigational
RomifidineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Romifidine.Vet Approved
RopiniroleTetracaine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Tetracaine.Approved
RotigotineTetracaine may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Tetracaine.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Tetracaine.Approved, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Tetracaine is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Tetracaine.Approved, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Tetracaine.Approved, Vet Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Tetracaine.Approved
StiripentolThe risk or severity of adverse effects can be increased when Tetracaine is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Tetracaine.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Tetracaine.Approved
SultoprideThe risk or severity of adverse effects can be increased when Tetracaine is combined with Sultopride.Experimental
SuvorexantTetracaine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when Tetracaine is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Tetracaine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Tetracaine is combined with Tasimelteon.Approved
Technetium Tc-99m tilmanoceptTetracaine may decrease effectiveness of Technetium Tc-99m tilmanocept as a diagnostic agent.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Tetracaine.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Tetrabenazine.Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Tetracaine.Investigational
ThalidomideTetracaine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Tetracaine.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Tetracaine.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Tetracaine.Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Tetracaine.Approved
TiagabineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Tetracaine is combined with Tiapride.Approved, Investigational
TiletamineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Tilidine.Experimental
TizanidineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Tizanidine.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tetracaine is combined with Tolcapone.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Tetracaine is combined with Topiramate.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Tetracaine.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Tetracaine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Tetracaine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Tetracaine.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Tetracaine.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Tetracaine is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Tetracaine is combined with Trichloroethylene.Experimental
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Tetracaine.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Tetracaine is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Tetracaine.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Triprolidine.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Tetracaine.Approved, Investigational
VenlafaxineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Tetracaine is combined with Veralipride.Experimental
VigabatrinThe risk or severity of adverse effects can be increased when Tetracaine is combined with Vigabatrin.Approved
Vinyl etherThe risk or severity of adverse effects can be increased when Tetracaine is combined with Vinyl ether.Experimental
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Tetracaine.Approved
XenonThe risk or severity of adverse effects can be increased when Tetracaine is combined with Xenon.Experimental
XylazineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Tetracaine.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Tetracaine is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Tetracaine.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Tetracaine is combined with Zolazepam.Vet Approved
ZolpidemTetracaine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Tetracaine is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Tetracaine.Approved
ZotepineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Zotepine.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Tetracaine.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference
Not Available
General References
Not Available
External Links
KEGG Drug
D00551
KEGG Compound
C07526
PubChem Compound
5411
PubChem Substance
310265012
ChemSpider
5218
BindingDB
50017659
ChEBI
9468
ChEMBL
CHEMBL698
PharmGKB
PA451638
HET
TE4
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Tetracaine
ATC Codes
D04AB06 — TetracaineN01BA03 — TetracaineS01HA03 — TetracaineC05AD02 — Tetracaine
AHFS Codes
Not Available
PDB Entries
Not Available
FDA label
Download (3.51 MB)
MSDS
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedSupportive CareCutaneous Abscess / Pain1
1CompletedBasic ScienceAnaesthesia therapy1
1CompletedBasic ScienceHealthy Volunteers2
1CompletedHealth Services ResearchPain1
1, 2CompletedTreatmentOsteoarthritis of the Knees1
2CompletedPreventionAnaesthesia therapy1
2CompletedSupportive CareAnaesthesia therapy1
2CompletedTreatmentAnaesthesia therapy3
2CompletedTreatmentAnesthetics, Local / Pain / Venipuncture1
2CompletedTreatmentCarpal Tunnel Syndrome (CTS)1
2CompletedTreatmentMyofascial Pain Syndromes1
2CompletedTreatmentPain1
2CompletedTreatmentPatellar Tendinopathy1
2CompletedTreatmentPostherpetic Neuralgia1
2CompletedTreatmentShoulder Impingement Syndrome1
2RecruitingPreventionNo Disease State or Condition1
2Unknown StatusTreatmentShoulder Pain1
2, 3Not Yet RecruitingTreatmentCorneal Abrasions1
3CompletedSupportive CareProcedural Pain Relief1
3CompletedTreatmentAnaesthesia therapy3
3CompletedTreatmentCataracts1
3CompletedTreatmentNewborn Infants / Pain1
3CompletedTreatmentPain6
3TerminatedTreatmentAnaesthesia therapy1
4CompletedPreventionAnesthesia of Mucous Membrane1
4CompletedSupportive CareArterial Catheterization1
4CompletedSupportive CarePain1
4CompletedTreatmentDermatitis Papillaris Capillitii / Tattooing1
4CompletedTreatmentDisseminated Sclerosis1
4CompletedTreatmentEpicondylitis of the Elbow1
4CompletedTreatmentHealthy Volunteers1
4CompletedTreatmentLocal Anesthesia of the Skin1
4CompletedTreatmentPain1
4CompletedTreatmentPain Associated With Epidural Needle Insertion1
4SuspendedBasic SciencePain1
4TerminatedSupportive CarePain1
4TerminatedTreatmentNasolabial Folds1
4WithdrawnNot AvailableFeeling Anxious / Pain1
4WithdrawnTreatmentAnaesthesia therapy / Healthy Volunteers1
Not AvailableCompletedNot AvailableAdverse Drug Events1
Not AvailableCompletedPreventionPain1
Not AvailableCompletedPreventionPharyngitis1
Not AvailableCompletedSupportive CareCataracts1
Not AvailableCompletedSupportive CarePain1
Not AvailableCompletedTreatmentAge-Related Macular Degeneration (AMD)1
Not AvailableCompletedTreatmentHysteroscopy1
Not AvailableNot Yet RecruitingPreventionHemodynamics Instability1
Not AvailableRecruitingPreventionArterial Hypotension1
Not AvailableTerminatedTreatmentLabour Pain1
Not AvailableUnknown StatusPreventionPain1
Not AvailableUnknown StatusTreatmentMacular Degeneration1
Not AvailableWithdrawnTreatmentPain1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
GelTopical40 mg
OintmentTopical2 g/100g
CreamTopical10 mg/mL
Aerosol, sprayTopical
SolutionTopical
LiquidTopical
AerosolTopical
GelDental
Aerosol, meteredTopical
Solution / dropsOphthalmic0.5 %
Solution / dropsOphthalmic1 %
CreamTopical20 mg/mL
CreamTopical20 mg/1000mg
Injection, powder, for solutionSubarachnoid10 mg/mL
CreamTopical20 mg/g
GelDental; Topical
GelBuccal
GelOral; Topical
CreamTopical
SolutionOphthalmic0.5 %
Solution / dropsOphthalmic.5 %
Powder, for solutionIntraspinal20 mg
KitInfiltration; Topical
LiquidInfiltration; Subcutaneous; Topical
LiquidParenteral; Topical
LiquidInfiltration
LiquidInfiltration; Subcutaneous
Aerosol, meteredDental754 mg
Aerosol, meteredOral; Topical11.6 mg
PatchCutaneous
InjectionSubarachnoid10 mg/mL
SolutionOphthalmic5 mg/mL
GelTopical20 mg/g
SprayTopical
LiquidOphthalmic25 mg/5mL
GelTopical2 %
CreamTopical2 %
GelTopical
AerosolOral
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6546281No1995-07-282015-07-28Us
US5658583No1995-07-282015-07-28Us
US6465006No1995-07-282015-07-28Us
US6465709No2000-07-072020-07-07Us
US6780426No1995-07-282015-07-28Us
US6306431No1995-07-282015-07-28Us
US5919479No1995-07-282015-07-28Us
US6528086No1999-09-282019-09-28Us
US8580282No2010-04-022030-04-02Us
US6413499No2000-03-202020-03-20Us
US9308191No2010-04-022030-04-02Us

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.555 mg/mLALOGPS
logP3.54ALOGPS
logP2.79ChemAxon
logS-2.7ALOGPS
pKa (Strongest Basic)8.42ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area41.57 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity80.17 m3·mol-1ChemAxon
Polarizability31.9 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-014i-0390000000-0435246ac53e48fff280
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-004i-0900000000-987e041aca4bd931c37e
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-004i-2900000000-8fb0dc9fe24fa06781f9
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-00fu-8900000000-13f5e95cf7277be78720
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0603-9500000000-43bdd69ad39be196db4d
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-004i-2910000000-a6e7d7e502323aaae4e8

Taxonomy

Description
This compound belongs to the class of organic compounds known as benzoic acid esters. These are ester derivatives of benzoic acid.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Benzoic acids and derivatives
Direct Parent
Benzoic acid esters
Alternative Parents
Aminobenzoic acids and derivatives / Phenylalkylamines / Benzoyl derivatives / Aniline and substituted anilines / Secondary alkylarylamines / Trialkylamines / Carboxylic acid esters / Amino acids and derivatives / Monocarboxylic acids and derivatives / Organopnictogen compounds
show 3 more
Substituents
Aminobenzoic acid or derivatives / Benzoate ester / Benzoyl / Aniline or substituted anilines / Phenylalkylamine / Secondary aliphatic/aromatic amine / Carboxylic acid ester / Amino acid or derivatives / Tertiary aliphatic amine / Tertiary amine
show 12 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
tertiary amino compound, benzoate ester (CHEBI:9468)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Modulator
General Function
Voltage-gated calcium channel activity
Specific Function
Calcium channel that mediates the release of Ca(2+) from the sarcoplasmic reticulum into the cytoplasm and thereby plays a key role in triggering muscle contraction following depolarization of T-tu...
Gene Name
RYR1
Uniprot ID
P21817
Uniprot Name
Ryanodine receptor 1
Molecular Weight
565170.715 Da
References
  1. Laver DR, van Helden DF: Three independent mechanisms contribute to tetracaine inhibition of cardiac calcium release channels. J Mol Cell Cardiol. 2011 Sep;51(3):357-69. doi: 10.1016/j.yjmcc.2011.05.009. Epub 2011 May 19. [PubMed:21624373]
  2. Lanner JT, Georgiou DK, Joshi AD, Hamilton SL: Ryanodine receptors: structure, expression, molecular details, and function in calcium release. Cold Spring Harb Perspect Biol. 2010 Nov;2(11):a003996. doi: 10.1101/cshperspect.a003996. Epub 2010 Oct 20. [PubMed:20961976]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Modulator
General Function
Suramin binding
Specific Function
Calcium channel that mediates the release of Ca(2+) from the sarcoplasmic reticulum into the cytoplasm and thereby plays a key role in triggering cardiac muscle contraction. Aberrant channel activa...
Gene Name
RYR2
Uniprot ID
Q92736
Uniprot Name
Ryanodine receptor 2
Molecular Weight
564562.71 Da
References
  1. Laver DR, van Helden DF: Three independent mechanisms contribute to tetracaine inhibition of cardiac calcium release channels. J Mol Cell Cardiol. 2011 Sep;51(3):357-69. doi: 10.1016/j.yjmcc.2011.05.009. Epub 2011 May 19. [PubMed:21624373]
  2. Lanner JT, Georgiou DK, Joshi AD, Hamilton SL: Ryanodine receptors: structure, expression, molecular details, and function in calcium release. Cold Spring Harb Perspect Biol. 2010 Nov;2(11):a003996. doi: 10.1101/cshperspect.a003996. Epub 2010 Oct 20. [PubMed:20961976]
3. Voltage gated sodium channel
Kind
Protein group
Organism
human
Pharmacological action
Yes
Actions
Antagonist
References
  1. Gammaitoni AR, Goitz HT, Marsh S, Marriott TB, Galer BS: Heated lidocaine/tetracaine patch for treatment of patellar tendinopathy pain. J Pain Res. 2013 Jul 19;6:565-70. doi: 10.2147/JPR.S46239. Print 2013. [PubMed:23888118]

Drug created on September 15, 2015 14:08 / Updated on October 02, 2017 06:13